Claims for Patent: 8,293,229

Summary for Patent: 8,293,229

Title:	Methods of producing stable pancreatic enzyme compositions
Abstract:	Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.
Inventor(s):	Ortenzi; Giovanni (Monza, IT), Marconi; Marco (Balsamo, IT), Mapelli; Luigi (Milan, IT)
Assignee:	Aptalis Pharma Limited (Wicklow, IE)
Application Number:	12/034,491
Patent Claims:	1. A method of preparing a pancrelipase composition comprising a plurality of particles comprising pancrelipase, wherein each said particle is coated with an enteric coating, comprising the steps of: coating the particles in an atmosphere wherein the atmosphere has a moisture content of about 3.6 g water per m.sup.3 or less, with a coating comprising an enteric polymer and at least one inorganic material, thereby forming a plurality of enterically coated particles wherein the particles have a moisture content of about 3% or less. 2. The method of claim 1, wherein the atmosphere comprises air, nitrogen, or an inert gas. 3. The method of claim 1, wherein the particles are coated with a mixture comprising an enteric polymer dissolved in acetone and at least one inorganic material. 4. A method of preparing a pancrelipase composition comprising a plurality of particles comprising pancrelipase, wherein each said particle is coated with an enteric coating, comprising: coating the particles in an atmosphere wherein the atmosphere has a moisture content of about 3.6 g water per m.sup.3 or less, with a coating comprising an enteric polymer and at least one inorganic material, thereby forming a plurality of enterically coated particles wherein the particles have a water activity of about 0.6 or less. 5. The method of claim 4, wherein the atmosphere comprises air, nitrogen, or an inert gas. 6. The method of claim 4, wherein the particles are coated with a mixture comprising an enteric polymer dissolved in acetone and at least one inorganic material. 7. The method of claim 1, wherein the particles exhibit a loss of digestive enzyme activity of no more than 25% after six months of accelerated stability testing. 8. The method of claim 7, wherein the atmosphere comprises air, nitrogen, or an inert gas. 9. The method of claim 7, wherein the particles of pancrelipase are coated with a mixture comprising an enteric polymer dissolved in acetone and at least one inorganic material. 10. The method of claim 3, wherein the enteric polymer is hydroxypropylmethylcellulose phthalate and the inorganic material is talc. 11. The method of claim 6, wherein the enteric polymer is hydroxypropylmethylcellulose phthalate and the inorganic material is talc. 12. The method of claim 9, wherein the enteric polymer is hydroxypropylmethylcellulose phthalate and the inorganic material is talc. 13. The method of claim 1, wherein the moisture content is about 0.5 g water per m.sup.3 or less. 14. The method of claim 4, wherein the moisture content is about 0.5 g water per m.sup.3 or less. 15. The method of claim 7, wherein the moisture content is about 0.5 g water per m.sup.3 or less. 16. The method of claim 7, wherein the loss of digestive enzyme activity is no more than 15% after six months of accelerated stability testing. 17. The method of claim 7, wherein the loss of digestive enzyme activity is no more than 12% after six months of accelerated stability testing. 18. The method of claim 7, wherein the loss of digestive enzyme activity is no more than 10% after six months of accelerated stability testing. 19. The method of claim 7, wherein the loss of digestive enzyme activity is no more than 8% after six months of accelerated stability testing. 20. The method of claim 7, wherein the loss of digestive enzyme activity is no more than 5% after six months of accelerated stability testing.

Details for Patent 8,293,229

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc.	COTAZYM	pancrelipase	Capsule, Delayed Release	020580	December 09, 1996	8,293,229	2027-02-20
Abbvie Inc.	CREON	pancrelipase	Capsule, Delayed Release	020725	April 30, 2009	8,293,229	2027-02-20
Abbvie Inc.	CREON	pancrelipase	Capsule, Delayed Release	020725	June 10, 2011	8,293,229	2027-02-20
Abbvie Inc.	CREON	pancrelipase	Capsule, Delayed Release	020725	March 14, 2013	8,293,229	2027-02-20

International Patent Family for US Patent 8,293,229

Country	Patent Number	Estimated Expiration
South Africa	200905630
World Intellectual Property Organization (WIPO)	2008102264
United States of America	8562981
United States of America	8562980